CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Memorial Sloan Kettering Cancer Center
University of Rochester
University of Washington
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
West Virginia University
The University of Queensland
National Institutes of Health Clinical Center (CC)
Quetzal Therapeutics
Technical University of Munich
National Institutes of Health Clinical Center (CC)
Kousai Bio Co., Ltd.
Universität Duisburg-Essen
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Immunome, Inc.
Orca Biosystems, Inc.
M.D. Anderson Cancer Center
Kura Oncology, Inc.
Incyte Corporation
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Pharmaceutical K.K.
Merck Sharp & Dohme LLC
Alliance for Clinical Trials in Oncology
University of Florida
University of Alabama at Birmingham
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University of Pennsylvania
St. Jude Children's Research Hospital
Beijing Biotech
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Kura Oncology, Inc.
Calibr, a division of Scripps Research
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center